Murdoch Children's Research Institute

News and Video Search Results

News coverage

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

GlobeNewswire 04 Jun 2024

- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained..

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
GlobeNewswire 13 May 2024
Stem Cell Collaboration, R&D, and Licensing Deals Analysis Report 2024 with Directory of 162 Agreements Signed Since 2016
GlobeNewswire 07 May 2024
Biotechnology Industry Insights: Comprehensive Report on Collaboration Deals from 2019-2024 Now Available
GlobeNewswire 05 Mar 2024
Pharmaceutical and Biotechnology Sector Insights: Comprehensive Analysis of Option and Evaluation Deals (2016-2024)
GlobeNewswire 05 Mar 2024

0 shares 1 views

You might like

Murdoch Children's Research Institute media coverage

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

Accesswire 16 Jan 2024

*Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical..

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
GlobeNewswire 13 Dec 2023
Food Allergy In Infancy Linked To Childhood Asthma And Reduced Lung Function
Eurasia Review 25 Jul 2023
Efforts To Tackle Diseases ‘Should Shift To Teens’
Eurasia Review 16 Jul 2023
Global Efforts To Reduce Infectious Diseases Must Extend Beyond Early Childhood
Eurasia Review 04 Jul 2023

Advertisement

More coverage

New research offers hope for kids like William, who survived 10 cardiac arrests
Brisbane Times 21 Mar 2023
New trial for childhood cancer treatment
Brisbane Times 25 Feb 2023